ClinicalTrials.gg
Enrolling by invitationNCT05697861Updated Aug 3, 2026

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

An observational study in Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy and Wild-Type Transthyretin Cardiac Amyloidosis, sponsored by Intellia Therapeutics. Enrolling by invitation at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Intellia Therapeutics · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
72
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.

Planned enrollment
9th of 12
72 · median 175
Started
2023
the only one that year
Observational
12 of 35
9 open now
Primary completion
2038-03
later than 15 of 15 live
Registered
26th of 35
by date
Lead sponsor
2 of 35
Intellia Therapeutics

Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 9th largest by planned enrollment of the 12 observational ones that give a count, is the only one that started in 2023, is one of 12 observational ones, reaches primary completion later than 15 of the 15 other live ones, and was the 26th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Amyloid Neuropathies, Familial with a site in France, or all of them as a file.
02

Study summary

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

03

Conditions studied

  • Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
  • Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
  • Wild-Type Transthyretin Cardiac Amyloidosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participating sites in an Intellia-sponsored clinical study of NTLA-2001.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.
  2. A subject has provided for the LTFU study.

Exclusion criteria

Exclusion Criteria:

None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
72 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-related SAEs and Protocol-specified AESIs

    Long-term safety assessment of any treatment-related SAEs and protocol-specified AESIs

    Time frame: up to 15 years

Secondary outcomes

  1. PD biomarkers for ATTR including serum TTR and serum prealbumin

    Long-term assessment of serum TTR and serum prealbumin

    Time frame: up to 15 years

07

Study locations

4 sites
  • Clinical Trial Site
    Paris, France
  • Clinical Trial Site
    Auckland, New Zealand
  • Clinical Trial Site
    Umeå, Sweden
  • Clinical Trial Site
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Mar 2038, 176 months after the start.

Of 74 observational studies under Amyloid Neuropathies, Familial, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 120. This study's planned 176 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2023
First posted
Jan 26, 2023
StartActual
Jul 10, 2023
Primary completionEst.
Mar 2038
CompletionEst.
Mar 2038
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05697861
Lead sponsor
Intellia Therapeutics
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Jul 10, 2023
Primary completion
Mar 2038 (estimated)
Completion
Mar 2038 (estimated)
Last update
Aug 3, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion